The Antiviral Compound for MERS-CoV

The Antiviral Compound for MERS-CoV

(From Potential Antiviral Agents for Coronaviruses: Compounds, Herbal Products, and Drug Targets)

  • A type of nucleoside analogues may be similar to the natural nucleosides that can block viral replication (Agostini et al., 2019).
  • Potent antiviral effects of a broad-spectrum ribonucleoside analogue, β-d-N4-hydroxycytidine (NHC) have been identified.
  • Studies found that viral proofreading activity did not influence the sensitivity to NHC inhibition (Agostini et al., 2019).
  • The finding refers to the interaction between a nucleoside analogue inhibitor and the CoV replicase.  
  • However, mutagenic nucleoside analogues including ribavirin and 5-fluorouracil may be ineffective.
  • This may be caused by the proofreading activity of the viral 3’-5’ exoribonuclease (ExoN).
  • NHC may inhibit multiple viruses including murine hepatitis virus (MHV) and Middle East respiratory syndrome CoV (MERS-CoV).
  • NHC may evade or overcome ExoN activity.
  • NHC inhibited MHV in the early stages of infection.
  • Further development of NHC may be helpful for finding broad-spectrum antivirals of CoV infections (Agostini et al., 2019).

References:

Agostini, M. L., Pruijssers, A. J., Chappell, J. D., Gribble, J., Lu, X., Andres, E. L., Bluemling, G. R., Lockwood, M. A., Sheahan, T. P., Sims, A. C., Natchus, M. G., Saindane, M., Kolykhalov, A. A., Painter, G. R., Baric, R. S., & Denison, M. R. (2019). Small-Molecule Antiviral β-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. Journal of Virology, 93(24).

This entry was posted in Infectious Diseases and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply